More questions than answers with esketamine, expert says
The trial that led to esketamine's FDA registration has just been published
31st May 2019
By Clare Pain
A leading US psychiatrist has urged caution on the use of intranasal esketamine, which was recently approved as a treatment for refractory depression by the country’s Food and Drug Administration.